Celgene wins in district court case, invalidating patent asserted against its Thalomid® and Revlimid® brand cancer drugs

Client(s) Celgene Corporation

Jones Day successfully defended Celgene Corporation in a patent infringement case brought in the United States District Court for the District of Delaware by Andrulis Pharmaceuticals Corporation, which alleged that Celgene's THALOMID® and REVLIMID® brand cancer drugs infringed U.S. Patent No. 6,140,346 ("'346 patent"). After Jones Day obtained a ruling that the asserted '346 patent claim is indefinite, the plaintiff agreed that the asserted claim is invalid and stipulated to the entry of a final judgment of invalidity.

Andrulis Pharmaceuticals Corp. v. Celgene Corp., 1:13-cv-01644 (D. Del.)